Contact

Paxman publishes newsletter on strong order flow from the USA, the UK and international markets

Today, Paxman publishes the September issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights that Paxman sees a continued strong order flow during the last month in line with the company's expectations. Orders were received from customers in 11 states in the USA, several existing customers in the UK and from customers in 10 international markets with a large regional spread (Armenia, Georgia, Turkey, Italy, Romania, Czech Republic, Brazil, India, Qatar and the United Arab Emirates). These international orders included 10 systems each from the distributor Praesidia to Italy and the distributor Incomed to the Netherlands.

The newsletter also includes information on that Paxman received market registration in Indonesia for the PSCS model of its scalp cooling system, completed training of partners from Turkey, Italy and Uruguay within the Paxman Distributor Training Certification Program and that the company notices that the number of visitors at physical events has now risen to pre-pandemic levels.

To read the newsletter and subscribe for upcoming issues, follow this link:

https://bit.ly/paxsep22en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram